David Taussig
The Royal Marsden, UK · Royal Marsden NHS Foundation Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Taussig as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:23 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04581512 · Study to Evaluate the Safety and Tolerability of EP0042Ellipses Pharma · recruiting · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes · principal investigator
- N/ANCT03233763 · Laboratory Studies Into the Pathology of LeukaemiaRoyal Marsden NHS Foundation Trust · unknown · Leukemia · principal investigator
- N/ANCT03026751 · Improving Diagnosis in Idiopathic Cytopenia Using Gene SequencingRoyal Marsden NHS Foundation Trust · unknown · Cytopenia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:23 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.Lancet Haematol · 2016377 citationsRCR 10.6
- 151 citationsRCR 6.9
- A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.Stem Cells Transl Med · 201491 citationsRCR 2.4
- A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.Blood Adv · 202281 citationsRCR 4.9
- Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.Blood Adv · 202278 citationsRCR 5.1
- 32 citationsRCR 2.8
- 18 citationsRCR 2.8
- Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.J Hematol Oncol · 202512 citationsRCR 2.8
- 7 citationsRCR 1.6
- 6 citationsRCR 0.2